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relationship between the oestrogenic activity (xenoestrogen)ntroduction
n recent years, exposure to certain chemical substances has
ecome a part of everyday life. Such is the case with bisphenol
 (BPA), or 2,2,-bis(4-hydroxyphenyl) propane, a molecule used
o synthesize polycarbonate plastics and epoxy resins. It is
sed extensively in the production of babies’ bottles, water
nd soft drinks bottles, and as the inner coating of cans and
ther food and drink containers. It is not surprising, then, that
n 2009 around 6 000 000 metric tonnes of BPA were generated
orldwide.1Numerous studies have demonstrated that more  than 90%
f the population in the USA have detectable urinary levels of
his compound and that the level of exposure of the population
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recent study conducted in Spain, Cutanda et al.3 reported that
BPA was present in the urine of 97% of the population studied.
Exposure to BPA occurs mainly via the oral route, but
also from dental sealants, through the skin, and by inhala-
tion of cleaning products. Even more  concerning is the fact
that studies conducted in Spain,4 China, and Japan.5 have
shown contamination of subterranean water and rivers with
BPA.
Numerous studies1,5–8 consider that BPA interfere with to
be an endocrine regulation. It has been studied the potentiala-Herrero N, Arenas MI, González-Santander M, et al. El bisfenol
Nefrología. 2016;36:5–9.
of BPA and different endocrine and metabolic abnormalities
including hepatic and thyroid disorders, obesity, insulin resis-
tance, and increased susceptibility to diabetes.9
vier España, S.L.U. This is an open access article under the CC
.
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From a renovascular perspective, the ﬁrst concerns
emerged in 2008 when Lang et al.10 found a signiﬁcant cor-
relation between a high urinary concentration of BPA and
cardiovascular diseases in patients with type 2 diabetes.8,10
The present review will analyse ﬁrst the critical role of renal
function on BPA excretion, and secondly will analyse the
experimental evidence that provides a solid scientiﬁc basis for
translational clinical studies that implicate BPA in renovascu-
lar damage.
Accumulation  of  bisphenol  A  in  patients  with
chronic  kidney  disease
It has been established that after ingestion, BPA is conjugated
in the liver with glucuronic acid, where it loses its oestrogenic
***
Control
N
um
be
r o
f p
od
oc
yt
es
BPA
12.5
10.0
7.5
5.0
2.5
0.0 
Control
A
B
C
Fig. 1 – BPA produces podocytopoenia in mice. (A) Immunohistoc
podocytes (brown nuclei) was lower than in controls. 300×. (B) T
immunohistochemistry for podocin (grey expansions). The renal
number of apoptotic podocytes than controls. 300×. (C) Left, grap
podocytes. Right, histogram representing the number of apoptot
using ANOVA for analysis of variance.
Source: Olea-Herrero et al.14 reproduced with permission. 6;3 6(1):5–9
activity and is then excreted to the intestine. Both BPA and its
metabolites are excreted in urine.1–3,6 Therefore, patients with
chronic kidney disease (CKD) have higher serum levels of BPA
than the general population11. A negative correlation has been
observed between estimated glomerular ﬁltration rate and the
serum concentration of BPA.7 A recent study by Krieter et al.,
analysed a cohort of 152 patients with CKD and 24 controls;
a signiﬁcant increase in plasma concentrations of BPA was
observed in CKD 3–5. The highest concentration of BPA was
obtained in patients with CKD 5 (dialysis) with values of up to
6 times higher than controls without kidney disease.11,12
Currently, the BPA clearance by dialysis has not been estab-
lished. This is a complex issue since the dialysis membranes
themselves contain variable amounts of BPA. This has been
proven by studies that demonstrate the presence of BPA in
the efﬂuents of polymethylmetacrylate, cellulose, cellulose
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Fig. 2 – BPA induces hypertension in mice. The mice were
treated with BPA at the doses indicated or with nothing
(controls). Blood pressure was assessed 30 days after the
administration of BPA. *P < .05 compared with
corresponding control (n = 10).n e f r o l o g i a
riacetate, polyester polymer, and polysulphone membranes,
articularly the latter.11–13 It has also been demonstrated
hat BPA levels can rise or remain unchanged after dialy-
is sessions. This may be due to the fact that BPA is highly
rotein-bound, at approximately 75%.11 Likewise, data were
nconclusive on the role of residual diuresis in BPA excretion
n CKD.11 Therefore, further studies are needed to clarify the
otential pathophysiological implications of BPA accumula-
ion in CKD, and to evaluate whether BPA should be added to
he long list of uraemic toxins.
isphenol  A  induces  podocyte  damage  and
roteinuria
 recent study described a new type of podocytopathy induced
y BPA.14 Olea-Herrero et al. observed that BPA could induce
ypertrophy and apoptosis in cultured mouse podocytes.
hese effects were accompanied by an increase in the syn-
hesis of molecules classically involved in the pathogenesis
f glomerulosclerosis, such as the cyclin-dependent kinase
nhibitor p27kip1, the TGF- system, and collagen IV. Further-
ore,  in these cells, BPA reduced the synthesis of nephrin and
odocin, proteins of the ﬁltration slits involved in the mech-
nisms of both proteinuria and podocyte survival. As would
e expected from these in vitro results, the kidneys of ani-
als treated with BPA developed hypertrophy, hyperﬁltration,
nd proteinuria. Along with the increased renal expression of
27kip1, TGF-, and collagen IV, mesangial expansion and a
ecrease in the number of podocytes due to apoptosis (Fig. 1)
ere also seen. Electron microscopy showed hypertrophy of
odocytes and pedicles. It should be noted that even when ani-
als treated with BPA did not develop hyperglycaemia, their
idneys showed structural and functional changes similar to
hose that occur in the initial stages of diabetic nephropa-
hy (DN). Although there are limitations to the use of animal
odels in the development of renal failure or long-term his-
omorphological renal changes,15 these ﬁndings may have
athophysiological implications, given that proteinuria is a
ood predictor of progression of kidney disease.16
isphenol  A  induces  endothelial  dysfunction
nd hypertension
ubsequent studies17 demonstrated that animals treated with
PA developed arterial hypertension and endothelial dys-
unction, in a dose-dependent manner. This effect could be
bserved at doses lower that half of those considered safe
Fig. 2). Microarray analysis of genetic expression in murine
ndothelial cells treated with BPA demonstrated the activation
f genes involved in vascular regulation such as angiotensin
I and calcium-calmodulin kinase II (CaMKII). This was subse-
uently observed in vivo as well. This activation is responsible
or the endothelial dysfunction and hypertension induced by
PA, given that CaMKII activation promotes the enzymatic
ncoupling of endothelial nitric oxide synthase. This leads to
he production of oxygen free radicals instead of nitric oxide, a
rimary vasodilator and endothelial protector. This increased
roduction of oxygen free radicals indicates that BPA, as wellSource:  Saura et al.17 reproduced with permission.
as inducing hypertension, could participate in vascular dam-
age mechanisms and in the progression of atherosclerotic
lesions.
Human  exposure  to  bisphenol  A  and
renovascular  damage
Recent studies have emphasised the interest of experimen-
tal rodent models for the study of BPA toxicity. It is important
to recognise that BPA has equal potency in human and ani-
mal  cells.18 Experimental data implicating BPA in renovascular
damage have gained particular relevance. Results obtained
experimentally are supported by epidemiological studies
conducted in the populations of New York,19 Shanghai,20
and Seoul,21 which describe an association between human
exposure to BPA and an increased in proteinuria and
hypertension.
From a nephrological perspective, two large popula-
tion studies should be mentioned. One of them was a
large adult Chinese population (N = 3077)20 and the other
involved 710 children in the United States.19 Both stud-
ies demonstrated a signiﬁcant association between urinary
excretion of BPA concentration and albuminuria. This asso-
ciation persisted independently of sex, diabetes, smoking
status, hypertension, or CKD. The authors of both stud-
ies speculated about the possible role of oxidative stress
and endothelial dysfunction to explain the ﬁndings. How-
ever, current experimental data show that even a low-grade
albuminuria associated with BPA exposure could promote
podocytopathy of uncertain (or at least unexplored) progno-
sis. This indicates the need to conduct further studies and
to re-evaluate the necessity of preventing or limiting BPA
exposure.
From a cardiovascular perspective, numerous clini-
cal and epidemiological studies have demonstrated that
. 2 0 1
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exposure to BPA is associated with hypertension and vascular
damage.22–25 In a sample representative of the adult USA pop-
ulation, Shankar and Teppala22 found that high urinary BPA
excretion was associated with arterial hypertension indepen-
dently of other classic risk factors. Similar results were found
in the adult population of Seoul, where 1511 analyses were
performed on 521 individuals.24 Likewise, Bae and Hong21
studied the acute effect of oral exposure to BPA in 60 people
following the ingestion of 2 servings of the same substance
(soya milk) packaged in either a can or a bottle: with canned
drinks, high urinary BPA was associated with increased blood
pressure 2 h after consumption.
There are various studies associating BPA exposure to vas-
cular damage. In Norfolk (United Kingdom), Melzer et al.24
evaluated 758 cases of coronary artery disease and 861 con-
trol subjects over a follow-up period of 10.8 years. They
demonstrated a signiﬁcant association between high uri-
nary BPA concentration and incident coronary artery disease.
Similar results have been published in studies from the
National Health and Nutritional Survey (NHANES) of the
USA25 in which the authors, after analysing 745 subjects,
found a signiﬁcant association between urinary BPA level
and peripheral arterial disease, independently of classic risk
factors.
The implications of these ﬁndings are obvious due to both
the high incidence in the population and the morbidity and
mortality of renovascular disease. It is well established that
cardiovascular disease is the most common cause of death in
developed countries, with approximately one quarter of the
population having some form of this disease.17,21–25 The same
may occur in CKD, in which BPA accumulates and could be
deemed a uraemic toxin.
It is difﬁcult to deﬁnitively characterise the potentially
harmful concentration of BPA. However, it is worth men-
tioning the ﬁndings of 2 independent studies in which the
consumption of a daily dose of canned beverage produced,
after 321 to 526 days, an increase in urinary BPA concen-
tration of over 1000% (over 20 ng/mL). Li et al.20 described
an association between BPA exposure and albuminuria in
adults, with some individuals having a mean urinary BPF
concentration of 1 ng/mL. Thus, the BPA exposure demon-
strated in repeated epidemiological studies, conducted mainly
in developed countries,27 is within the range associated with
proteinuria and hypertension.
In addition, since the end of the last century, a worldwide
epidemic of type 2 diabetes – the most common cause of
CKD in developed countries – has been detected. Data from
the Registry of the Spanish Society of Nephrology estimate
that in 21% of patients, CKD is caused by Diabetic Nephropa-
thy (DN).26 Although classically DN has been considered a
metabolic disease, studies by Navarro et al.28 demonstrated
the presence of an inﬂammatory component of DN. Given that
only 20–40% of patients with diabetes develop nephropathy, it
is suggested that there are other (genetic) diabetes-inducing
factors involved that are yet to be discovered.29 Current inves-
tigations allow us to hypothesise that the environmental
factor BPA may induce or potentiate changes in the kid-
ney that occur in diabetes mellitus. It is worth mentioning,
ﬁnally, that in USA the FDA has proposed to sponsor research
on BPA.30 6;3 6(1):5–9
Conclusions
The available scientiﬁc data allow the identiﬁcation of BPA as
a new environmental factor implicated in renovascular dam-
age. This is characterised by podocytopathy with proteinuria,
arterial hypertension, and vascular dysfunction. These data
also support the need for translational studies in an attempt
to clarify the potential role of BPA in hypertension and in the
progression of kidney disease, particularly in patients with
diabetes.
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